Sign In
Buy NLSP
$0.762
+0 (+0%)
At Close: Mar 11, 2026
ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
07:00am, Monday, 04'th Nov 2024
ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd.
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
07:00am, Monday, 28'th Oct 2024
ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
07:00am, Monday, 21'st Oct 2024
ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to develop
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
07:00am, Tuesday, 15'th Oct 2024
ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
08:00am, Wednesday, 25'th Sep 2024
ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
12:03pm, Monday, 29'th Jul 2024
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
11:30am, Monday, 29'th Jul 2024
NLS Pharmaceutics (NASDAQ: NLSP ) stock is on the rise Monday after the clinical-stage biopharmaceutical company announced a merger agreement with Kadimastem. This agreement will see Kadimastem acquir
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
07:00am, Monday, 29'th Jul 2024
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell the
NLS Pharmaceutics Announces Registered Direct Offering
09:00am, Friday, 28'th Jun 2024
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discover
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
08:00am, Thursday, 27'th Jun 2024
ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
08:30am, Tuesday, 25'th Jun 2024
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therap
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
08:38am, Thursday, 20'th Jun 2024
NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock clos
Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?
07:54am, Tuesday, 18'th Jun 2024
NLS Pharmaceutics (NASDAQ: NLSP ) stock is rocketing higher on Tuesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 73 million share
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
08:30am, Tuesday, 11'th Jun 2024
ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering
